Altre lingue Oncotelic Therapeutics, Inc.

Azioni

OTLC

US6283411097

Tempo differito OTC Markets Altri mercati azionari 17:49:04 01/05/2024			Variaz. 5gg	Var. 1 gen.
0,0388 ^USD	-2,88%		+7,78%	+1,31%

12/04	Oncotelic Therapeutics, Inc. riporta i risultati degli utili per l'intero anno terminato il 31 dicembre 2023	CI
25/03	Oncotelic Therapeutics, Inc. annuncia il collegamento tra cancro e lupus nei pazienti affetti da gliomi	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Oncotelic Therapeutics, Inc. to Sell Its Necroptosis Cancer Therapy Assets to Mosaic ImmunoEngineering, Inc.	29/04
Oncotelic Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	12/04
Oncotelic Therapeutics, Inc. - Linkage of Cancer and Lupus in Gliomas Patients	26/03
Linkage of Cancer and Lupus in Gliomas Patients	25/03
Oncotelic Therapeutics, Inc. Announces Linkage of Cancer and Lupus in Gliomas Patients	25/03
Invitation to Participate in STOP-PC Clinical Trial	04/03
Diffuse Intrinsic Pontine Glioma Pipeline, FDA Approvals, Clinical Trials Developments, and Companies 2024 (Updated)	21/02
Oncotelic Therapeutics Announces Clinical Linkage of TGFB2 and IFNGR2 in Pediatric DMG Patients	16/01
Diffuse Intrinsic Pontine Glioma Pipeline, FDA Approvals, Clinical Trials Developments, and Companies 2023 (Updated)	22/12
Oncotelic Therapeutics Announces Opening of GMP Manufacturing Plant	18/12
Oncotelic Therapeutics Announces CEO to Discuss Proprietary AI Technology at Ibero-American Chatbot Summit	29/11
Oncotelic Therapeutics Announces CEO To Discuss Proprietary AI Technology at Ibero-American Chatbot Summit.	28/11
Earnings Flash (OTLC) ONCOTELIC THERAPEUTICS Posts Q3 Revenue $70,000	15/11
Oncotelic Reports Q3 2023 Compared to Q3 2022 Financial Results	15/11
Oncotelic Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11
Oncotelic Therapeutics, Inc. announces tranche update	24/10/23
Oncotelic Therapeutics, Inc. Awarded Top Cancer Immunotherapy Solutions Provider 2023	28/08/23
Oncotelic Therapeutics, Inc. Awarded Top Cancer Immunotherapy Solutions Provider 2023	25/08/23
Sapu BioScience and Cromos Pharma initiating P201 – A Registrational trial for OT-101 in Pancreatic Cancer	23/08/23
Oncotelic Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	18/08/23

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Oncotelic Therapeutics, Inc.

Azioni

OTLC

US6283411097

Altre lingue

Filtri